Assessing Pre-Existing Antibodies in DMD Patients
Time: 2:00 pm
day: Conference Day One
Details:
- Analysing the dose-dependent relationship between AAV titer, complement activation, and potential off-target effects in systemic gene therapy
- Exploring the rationale and potential limitations of co-administration of complement inhibitors with systemic AAV vectors
- Discussing the potential of next-gen vectors with reduced complement recognition for improved systemic delivery
